Early-onset Schizophrenia — Reward Processing in Mental Illness
Citation(s)
Barch DM, Dowd EC Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull. 2010 Sep;36(5):919-34. doi: 10.1093/schbul/sbq068. Epub 2010 Jun 21. Review.
Berridge KC The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl). 2007 Apr;191(3):391-431. Epub 2006 Oct 27. Review.
Bleuler, E Dementia Praecox or the Group of Schizophrenias. (1911) (International Universities Press, New York, NY, Translated by J. Zinkin, 1950).
Braver TS, Barch DM, Cohen JD Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function. Biol Psychiatry. 1999 Aug 1;46(3):312-28. Review.
Bromberg-Martin ES, Matsumoto M, Hikosaka O Dopamine in motivational control: rewarding, aversive, and alerting. Neuron. 2010 Dec 9;68(5):815-34. doi: 10.1016/j.neuron.2010.11.022. Review.
Carver, C S. & White, T. L. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS Scales. Journal of Personality and Social Psychology 67,319-333 (1994).
Chiew KS, Braver TS Positive affect versus reward: emotional and motivational influences on cognitive control. Front Psychol. 2011 Oct 19;2:279. doi: 10.3389/fpsyg.2011.00279. eCollection 2011.
Cohen JD, Braver TS, Brown JW Computational perspectives on dopamine function in prefrontal cortex. Curr Opin Neurobiol. 2002 Apr;12(2):223-9. Review.
Dowd EC, Barch DM Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia. PLoS One. 2012;7(5):e35622. doi: 10.1371/journal.pone.0035622. Epub 2012 May 4.
Egner T, Hirsch J Cognitive control mechanisms resolve conflict through cortical amplification of task-relevant information. Nat Neurosci. 2005 Dec;8(12):1784-90. Epub 2005 Nov 6.
Fagerström KO Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3(3-4):235-41.
Fenton WS, McGlashan TH Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry. 1991 Nov;48(11):978-86.
First, M , Spitzer, R., Gibbon, M. & Williams, J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). (New York State Psychiatric Institute, 2002).
Gard DE, Kring AM, Gard MG, Horan WP, Green MF Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007 Jul;93(1-3):253-60. Epub 2007 May 9.
Gehring WJ, Willoughby AR The medial frontal cortex and the rapid processing of monetary gains and losses. Science. 2002 Mar 22;295(5563):2279-82.
Gold JM, Waltz JA, Prentice KJ, Morris SE, Heerey EA Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull. 2008 Sep;34(5):835-47. doi: 10.1093/schbul/sbn068. Epub 2008 Jun 30. Review.
Haber SN, Knutson B The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology. 2010 Jan;35(1):4-26. doi: 10.1038/npp.2009.129. Review.
Heinz A, Schlagenhauf F Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull. 2010 May;36(3):472-85. doi: 10.1093/schbul/sbq031. Epub 2010 May 7. Review.
Hollingshead AB, Redlich FC Social class and mental illness: a community study. 1958. Am J Public Health. 2007 Oct;97(10):1756-7.
Horan WP, Foti D, Hajcak G, Wynn JK, Green MF Impaired neural response to internal but not external feedback in schizophrenia. Psychol Med. 2012 Aug;42(8):1637-47. doi: 10.1017/S0033291711002819. Epub 2011 Dec 8.
Horan WP, Kring AM, Gur RE, Reise SP, Blanchard JJ Development and psychometric validation of the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res. 2011 Nov;132(2-3):140-5. doi: 10.1016/j.schres.2011.06.030. Epub 2011 Jul 27.
Kapur S Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003 Jan;160(1):13-23. Review.
Kay SR, Fiszbein A, Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.
Krawczyk DC, Gazzaley A, D'Esposito M Reward modulation of prefrontal and visual association cortex during an incentive working memory task. Brain Res. 2007 Apr 13;1141:168-77. Epub 2007 Jan 25.
Kriegeskorte N, Lindquist MA, Nichols TE, Poldrack RA, Vul E Everything you never wanted to know about circular analysis, but were afraid to ask. J Cereb Blood Flow Metab. 2010 Sep;30(9):1551-7. doi: 10.1038/jcbfm.2010.86. Epub 2010 Jun 23. Review.
Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry. 2013 Feb;170(2):165-72. doi: 10.1176/appi.ajp.2012.12010109.
Kring AM, Moran EK Emotional response deficits in schizophrenia: insights from affective science. Schizophr Bull. 2008 Sep;34(5):819-34. doi: 10.1093/schbul/sbn071. Epub 2008 Jun 25. Review.
Milev P, Ho BC, Arndt S, Andreasen NC Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005 Mar;162(3):495-506.
Miller R Schizophrenic psychology, associative learning and the role of forebrain dopamine. Med Hypotheses. 1976 Sep-Oct;2(5):203-11.
Miltner WH, Braun CH, Coles MG Event-related brain potentials following incorrect feedback in a time-estimation task: evidence for a "generic" neural system for error detection. J Cogn Neurosci. 1997 Nov;9(6):788-98. doi: 10.1162/jocn.1997.9.6.788.
Morris SE, Heerey EA, Gold JM, Holroyd CB Learning-related changes in brain activity following errors and performance feedback in schizophrenia. Schizophr Res. 2008 Feb;99(1-3):274-85. Epub 2007 Sep 24.
Morris SE, Holroyd CB, Mann-Wrobel MC, Gold JM Dissociation of response and feedback negativity in schizophrenia: electrophysiological and computational evidence for a deficit in the representation of value. Front Hum Neurosci. 2011 Oct 28;5:123. doi: 10.3389/fnhum.2011.00123. eCollection 2011.
O'Connor DA, Rossiter S, Yücel M, Lubman DI, Hester R Successful inhibitory control over an immediate reward is associated with attentional disengagement in visual processing areas. Neuroimage. 2012 Sep;62(3):1841-7. doi: 10.1016/j.neuroimage.2012.05.040. Epub 2012 May 25.
Oldfield RC The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971 Mar;9(1):97-113.
Pessoa L How do emotion and motivation direct executive control? Trends Cogn Sci. 2009 Apr;13(4):160-6. doi: 10.1016/j.tics.2009.01.006. Epub 2009 Mar 13.
Stein L, Wise CD Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science. 1971 Mar 12;171(3975):1032-6.
Walsh MM, Anderson JR Learning from experience: event-related potential correlates of reward processing, neural adaptation, and behavioral choice. Neurosci Biobehav Rev. 2012 Sep;36(8):1870-84. doi: 10.1016/j.neubiorev.2012.05.008. Epub 2012 Jun 7. Review.
Waltz JA, Frank MJ, Robinson BM, Gold JM Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry. 2007 Oct 1;62(7):756-64. Epub 2007 Feb 14.
Watanabe M, Sakagami M Integration of cognitive and motivational context information in the primate prefrontal cortex. Cereb Cortex. 2007 Sep;17 Suppl 1:i101-9. Review.
Wechsler, D Wechsler Test of Adult Reading., (Psychological Corporation, 2001).
Weissman, A The Dysfunctional Attitudes Scale: A validation study., University of Pennsylvania, (1973).
Multimodal Neural Investigation of Reward Processing in Mental Illness
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.